Home  |  Important Safety Information  |  Full Prescribing Information PDF  |  Contact Us  |  Site Map
Register for More Information  |  Send to a Friend
A
A
A
Print

Taking FROVA®

About FROVA

FROVA is a prescription medicine used to treat migraine attacks in adults. It is in the class of drugs called selective serotonin receptor agonist.23

FROVA should only be taken for a migraine headache. Do not use FROVA to treat headaches that might be caused by other conditions. Tell your doctor about your symptoms. Your doctor will decide if you have migraine headaches and if FROVA is right for you.23

Take one FROVA tablet anytime after the start of your migraine headache. If your headache comes back after your first dose, you may take a second tablet after two (2) hours. Do not take more than three (3) FROVA tablets in a 24-hour period.

If you take too much medicine, contact your doctor, hospital emergency department, or poison control center right away.23

A study showed that early migraine treatment (vs. late) with FROVA is more likely to produce pain relief.18

What to do next:

Listen to Sue's story
Talk to your doctor about migraine
View profiles of migraine sufferers

The most common side effects associated with the use of FROVA are dizziness, tiredness, feeling of tingling, hot flashes, headache (other than migraine headache), dry mouth, hot or cold sensation, pain in joints or bones, chest pain, and indigestion.
+ View references
  1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. 2nd ed. Cephalalgia. 2004;24(suppl 1):24-36; 138-149. Available at: http://216.25.100.131/ihscommon/guidelines/pdfs/ihc_II_main_no_print.pdf. Accessed January 19, 2007.
  2. American Council for Headache Education. Headache diary. Available at: http://www.achenet.org/resources/diary.php. Accessed February 21, 2007.
  3. National Headache Foundation. Serotonin. Available at: http://www.headaches.org/consumer/topicsheets/serotonin.html. Accessed February 21, 2007.
  4. American Council for Headache Education. Women and headaches. Available at: http://www.achenet.org/news/women.php. Accessed February 21, 2007.
  5. American Council for Headache Education. Migraine and coexisting conditions. Available at: http://www.achenet.org/news/macc.php. Accessed February 21, 2007.
  6. Lichten EM, Lichten JB, Whitty A, Pieper D. The confirmation of a biochemical marker for women's hormonal migraine: the Depo-Estradiol challenge test. Headache. 1996;36:367-371.
  7. MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3:354-361.
  8. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
  9. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. Headache. 1993;33:385-389.
  10. Dzoljic E, Sipetic S, Vlajinac H, et al. Prevalence of menstrually related migraine and nonmigraine primary headache in female students of Belgrade University. Headache. 2002;42:185-193.
  11. Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia. 2004;24:707-716.
  12. Couturier EGM, Bomhof MAM, Knuistingh Neven A, van Duijn NP. Menstrual migraine in a representative Dutch population sample: prevalence, disability and treatment. Cephalalgia. 2003;23:302-308.
  13. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology. 2004;63:351-353.
  14. Martin VT, Wernke S, Mandell K, et al. Defining the relationship between ovarian hormones and migraine headache. Headache. 2005;45:1190-1201.
  15. MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(72):2154-2158. doi: 10.1212/01.wnl.0000233888.18228.19.
  16. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63:261-269.
  17. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000; 55:754-762.
  18. Cady R, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Res Med Opin. 2004; 20(9):1465-1472. doi: 10.1185/030079904x2745.
  19. FROVA® [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
  20. Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006;46(6):942-953. doi:10.1111/j.1526-4610.2006.00443.x.
  21. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006;46(5):773-780. doi:10.1111/j.1526-4610.2006.00437.x.
  22. Guidelines for controlled trials of drugs in migraine. First edition. International Headache Society Committee on Clinical Trials in Migraine. Cephalalgia. 1991;11(1):1-12.
  23. FROVA® Patient Product Information. Chadds Ford, PA: Endo Pharmaceuticals; 2007.
     

    Important Safety Information

    For more information, please see Full Prescribing Information for FROVA at http://www.frova.com/pi.